Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

Xiangyu Gao; Nong Xu; Ziyu Li; Lin Shen; Ke Ji; Zhong Zheng; Dan Liu; Hanmei Lou; Li Bai; Tianshu Liu; Yunxia Li; Yuzhi Li; Qingxia Fan; Feng Mei; Haijun Zhong; Yi Huang; Ge Lou; Jing Wang; Xiaoyan Lin; Ye Chen; Ruifang An; Changzheng Li; Qi Zhou; Xin Huang; Zengqing Guo; Shubin Wang; Guiling Li; Junwei Fei; Lijing Zhu; Hong Zhu; Xiu-Min Li; Fenghu Li; Sihai Liao; Qinghua Min; Lei Tang; Fei Shan; Jifang Gong; Yunong Gao; Jun Zhou; Zhihao Lü; Xiaofan Li; Jianjie Li; Hui Ren; Xiaohong Liu; Hongxia Yang; Wenting Li; Weifeng Song; Zhongmin Maxwell Wang; Baiyong Li; Michelle Xia; Xiaohua Wu; Jiafu Ji

doi:10.1016/s1470-2045(23)00411-4

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

Xiangyu Gao(Peking University), Nong Xu(Zhejiang University), Ziyu Li(Peking University Cancer Hospital), Lin Shen(Peking University), Ke Ji(Peking University), Zhong Zheng(Fudan University Shanghai Cancer Center), Dan Liu(Peking University), Hanmei Lou(Zhejiang Cancer Hospital), Li Bai(Chinese PLA General Hospital), Tianshu Liu(Zhongshan Hospital), Yunxia Li(Ningxia Medical University), Yuzhi Li(First Affiliated Hospital of Bengbu Medical College), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Feng Mei(Fujian Provincial Cancer Hospital), Haijun Zhong(Zhejiang Cancer Hospital), Yi Huang(Hubei Cancer Hospital), Ge Lou(Third Affiliated Hospital of Harbin Medical University), Jing Wang(Hunan Cancer Hospital), Xiaoyan Lin(Fujian Medical University), Ye Chen(First Affiliated Hospital of Henan University of Science and Technology), Ruifang An(First Affiliated Hospital of Xi'an Jiaotong University), Changzheng Li(Shandong First Medical University), Qi Zhou(Chongqing University), Xin Huang(Sun Yat-sen University Cancer Center), Zengqing Guo(Fujian Provincial Cancer Hospital), Shubin Wang(Peking University Shenzhen Hospital), Guiling Li(Wuhan Union Hospital), Junwei Fei(First Bethune Hospital of Jilin University), Lijing Zhu(Nanjing Drum Tower Hospital), Hong Zhu(Central South University), Xiu-Min Li(Peking University), Fenghu Li(Guizhou Cancer Hospital), Sihai Liao(Guangdong Medical College), Qinghua Min(First Affiliated Hospital of Nanchang University), Lei Tang(Peking University), Fei Shan(Peking University), Jifang Gong(Peking University Cancer Hospital), Yunong Gao(Peking University Cancer Hospital), Jun Zhou(Peking University Cancer Hospital), Zhihao Lü(Peking University), Xiaofan Li(Peking University Cancer Hospital), Jianjie Li(Peking University Cancer Hospital), Hui Ren(Peking University), Xiaohong Liu(Peking University Cancer Hospital), Hongxia Yang(Peking University Cancer Hospital), Wenting Li, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Xiaohua Wu(Fudan University Shanghai Cancer Center), Jiafu Ji(Peking University)

The Lancet Oncology

October 1, 2023

10.1016/s1470-2045(23)00411-4

Cited by 193

Abstract

Related Papers

No related papers found

Powered by citation graph analysis